Ads
related to: Pfizer
Search results
Pfizer gets EU backing for new antibiotic combination (NYSE:PFE)
Seeking Alpha· 7 days agoPfizer's novel antibiotic combination, Emblaveo, receives positive opinion from EU drug regulator...
Pfizer (PFE) Gains As Market Dips: What You Should Know
Zacks· 4 days agoFree Report) ending at $27.43, denoting a +0.26% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.31%. Heading into today, shares of the ...
Argus cuts Pfizer to hold, cites concerns about topline growth (NYSE:PFE)
Seeking Alpha· 7 days agoArgus downgrades Pfizer (PFE) to hold due to concerns about its topline growth and setbacks in its...
Johnson & Johnson is suing a former Philly-area employee, saying he took trade secrets to Pfizer
Philly.com· 2 days agoPharmaceutical giant Johnson & Johnson is suing a former employee from Doylestown that it alleges...
Former Pfizer Lawyer, Blue Buffalo GC Takes Legal Reins at Bioweapon Fighting Pharma Company |...
Law.com· 3 days agoLarry Miller, a former senior in-house attorney at Pfizer and general counsel of Blue Buffalo, has...
Pfizer CEO Albert Bourla is still a human
Politifact· 4 days agoPfizer CEO Albert Bourla regularly comes under scrutiny from people critical of COVID-19 vaccines. "The Pfizer CEO is a reptile confirmed?" reads the...
Redhawk Wealth Advisors Inc. Purchases 538 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 6 days agoRedhawk Wealth Advisors Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 5.2% during the 4th quarter, according to its most recent filing with ...
Americans would be scared to drive cars designed like COVID vaccines: ex-Pfizer trial pioneer
Just the News· 6 days agoCOVID-19 vaccines are safe and effective – assuming the federal government consistently updates...
After terminating 1 of 2 late-stage sickle cell disease trials, Pfizer still expects FDA approval in...
FierceBiotech· 2 days agoPfizer had been running a pair of trials under a program known as “THRIVE” to evaluate inclacumab, a...
Argus downgrades Pfizer, lowers earnings estimates on 'near-term headwinds' By Investing.com
Investing.com· 7 days agoArgus downgrades Pfizer, lowers earnings estimates on 'near-term headwinds'